• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A compound is disclosed which has the formula, <IMAGE> where R1 is a hydrogen atom, or a straight or branched chain alkyl group having 1 to 4 carbon atoms, and R2 is a straight or branched chain alkyl group having 1 to 4 carbon atoms, <IMAGE> +TR <IMAGE> in which n is an integer of 0 to 3, or a pharmaceutically acceptable salt thereof. A process for producing the compound and a medicine containing the compound are also disclosed. Such medicine is effectively useful for inhibiting myocardial infarction.
    公开号:SU1318161A3
    申请号:SU823419752
    申请日:1982-04-09
    公开日:1987-06-15
    发明作者:Масаки Томох；Камисиро Тосиро；Окадзае Такаси；Кумакура Коити；Масаки Митсуо
    申请人:Ниппон Кемифар Ко,Лтд (Фирма)；
    IPC主号:
    专利说明:

    /
    SNG
    some of the general formula II, containing an eprxy group, or €; o potassium salt. 3. The method of obtaining € piperazine derivatives of general formula 1a
    n Q CONH-CH-C (
    XH
     n
      .СН1Шг 2
    where R is an alkyl group containing 1-4 carbon atoms,
    RJ - 2,3,4-trimethoxyphenylmethyl,
    (2-pyrimidinyl),
    or their pharmaceutically acceptable salts, characterized in that the compound of the general formula V
    This invention relates to a process for the preparation of new piperazine derivatives of general formula I
    H .0 CQKH-m-CO - NQNKg 5
    RjOOC n t
    CH (SS) g.
    de r r. HYDROGEN, a straight or branched chain alkyl group containing 1-4 carbon atoms;
    straight chain alkyl group containing 1-4 carbon atoms,
    (o} (OSNz) „, where
    , cinnamyl, diphenylmethyl, (2 - pyridinyl), (2-pyrimidinyl),
    or their pharmaceutically acceptable salts, which are e (3) effective agents for the prevention and treatment of myocardial infarction.
    The aim of the invention is to develop a method for the production of piperazine derivatives, imposing a new type of activity, namely, an inhibitory effect in the treatment or prevention of myocardial infarction, as well as low toxicity.
    CONH-CH-COOH and CH2. . CHiCH H
    where R has the indicated meanings, is reacted with a compound of general formula VI
    HNQN-RS
    where RJ- is as defined,. in the presence of condensing agents — N-oxysuccinimide or N-hydroxy-benzotriazole and N, N-dicyclohexyl-carbodiimide in ethyl acetate.
    five
    0
    five
    0
    ABOUT
    Example 1. In 100 ml of a methylene chloride solution containing 9.96 g of tert-butoxycarbonyl-b-leucine monohydrate and 4.6 g of N-oxysuccinimide, 50 nl of a solution of 8.24 g of N, N is added dropwise. dicyclohexyl-carbodiimide in methylene chloride for 1 hour while cooling with ice. After stirring at room temperature for 4 hours, the reaction mixture is cooled again with ice and 50 ml of a methylene chloride solution of 10.08 g of 1- (diphenylmethyl) piperazine are added to it over 20 minutes. The mixture was then stirred overnight at room temperature. The precipitate was filtered off, the solvent was removed by distillation in vacuo under pressure, and ethyl acetate was added. After removing all the undissolved material by filtration again, the filtrate is washed first with an aqueous solution of sodium bicarbonate and then with a saturated solution of sodium chloride, dried over magnesium sulfate and distilled in vacuo to remove the solvent. The obtained reaction residue is purified by chromatographic treatment in a column with silica gel (the development solvent is chloroform, and then a mixture of chloroform with methanol in a ratio of 50: 1). Receive 16.5 g (89%) of tertiary 313181
    (3) -1- (4-diphenyl-methyl-piperazin-1-yl-carbonyl) -3-methyl-butyl-carbamic acid -butyl ester as a colorless amorphous substance.
    NMR spectrum (CBCI3), cU: 0.86 (3N, 5 d (CHj) CH -); o, 92 (3H, d, (CH3) 2 (CH-)); 1.38 (9H, S (CHj ) 5C-), 1.3-1.9 (ZN, t,); 2.3 (4H, t,
    -CON
     CH i-CH i
    X
    ;-TO-
    CON
    CH-i-CH /
    , 12 (1H, s,
     -CYAg) -, 4.48 (1H, t, NH-CH-CO-) 5.18 (W, Lg, -NH); 7.0-7.3 (YUN, t, aromatic protons),
    While cooling with ice and passing a stream of gaseous hydrogen chloride, a saturated solution of it in 300 ml of ethyl acetate is prepared and 80 ml of an ethyl acetate solution of 16.5 g of the obtained tert-butyl ether (S) 1 are added dropwise to this solution for 10 minutes. - (4-diphenylmethyl-piperazin-1-ylcarbonyl) -3-methylbutylcarbamic acid. The mixture is stirred for 2 hours at room temperature, the solvent and residual hydrogen chloride are continuously removed by distillation under reduced pressure, to obtain 15.6 g (100%) of 4-diphenylmethyl-1r (L) -leuishI piperazine dihydrochloride in the form of light yellow crystals .
    A solution of 7.31 g of N, N-d; icyclohexylcarbodiimil in 50 ml of methylene chloride is added to a solution of 5.68 g of monoethyl transepoxysuccinate and 4.08 p of N-oxysuccinimide in 100 ml of chloride under ice cooling for 1 h. methylene. After stirring at room temperature for 4 hours, the mixture is cooled again with ice, after which 15.6 g of the 4-diphenylmethyl-1-L-leucylpiperazine dihydrochloride obtained are added. Next, 7.9 g of triethylamine are added dropwise over 5 mil. and the mixture is stirred over night at room temperature. After removing the solvent by distillation under reduced pressure, 250 ml of ethyl acetate was added to the residue. The reaction mass is filtered, the filtrate is washed first with water.
    0
    five
    0
    0

    five
    0
    614
    sodium bicarbonate solution and then aqueous saturation with sodium chloride solution, dried over magnesium sulfate and the solvent is distilled off under reduced pressure. The resulting reaction mixture was purified by chromatography on a column of silica gel (the development solvent was chloroform, and then a mixture of chloroform and methanol in a 50: 1 ratio), to obtain 13.3 g (7 4%) of ethyl-α-trans-3- (3 ) -1- (4-difensh1methylpiperazin-1-ylcarbonyl) -3-methylbutylcarbamoyl2-oxiran-2-carboxate 1 as a light yellow amorphous substance.
    While cooling with ice, 0.48 dropwise, n, a solution of sodium hydroxide in ethanol (54.2 ml) was added to 70 ml of an ethanol solution of 13.2 g of ethyl-trans-3- (S) -1 - (4 -diphenylmethylpiprazin-1-ylcarbonyl) -3-methylbutylcarbamoyl -oxyran-2-carboxylate. After stirring at room temperature for 3 hours, the solvent was removed by distillation under reduced pressure and the reaction mixture was further dried under reduced pressure to give 12.4 g (95%) trans-3- -T (8) -1- (4-diphenylmethyl-piperazin-1- -ylcarbonyl) -3-methylbutylcarbamoyl-sodium-oxirane-2-carboxylate as a pale yellow powder.
    The sodium salt thus obtained is added to an equivalent amount of 0.1N. hydrochloric acid solution. The precipitated white crystals are collected by filtration, washed with cold water and dried under reduced pressure to obtain the corresponding free acid with a melting point of 129-132 ° C (with decomposition),
    IR spectrum (KVg): 1640, 890 cm.
    NMR (CDiCD): 0.90 (6H, d, -CH (CHj).); 1.4-1.7 (3N, m, -CH-CH (CH3) g); 2.5 (4H, t,
    .
    -CON: -N-3.3-3.8 (bn, .2
    t.
    -CQ-N
    five
    / w, -sn,
    CHT-CHX
    risih - sn-n-
    .4.36 (1H; S, -CH () 2), 4.8 (1H, t, 11 - CH-CO-); 7.1-7.3 (YUN, t, -CH (CtHs) i),
    Mass Spectrum (m / e); 480 (M + 1) 479- (M); 167 (100%).
    Calculated,%: C 67.62j H N 8.76.
    C ,, H, N, 0.5
    Found,%: С 67 „45} H 7.05; N 8.55.
    Example 2. A condensation reaction of 8.92 g of tert-butoxycarbonyl-L-leucine monohydrate and 6.30 g of 1-benzylpiperazine is carried out angstaghically the process for the preparation of tert-butyl ether (S) -1- (4-difelyme methylpiperase) -1-yl-carbonyl) -3-methylbutylcarbamic acid. 8.06 g (58%) of (S) -1- (4-β-benzylpiperazin-1-ylcarbonyl) -3-methyl-butylcarbamic acid tert-butyl ester are obtained as a colorless amorphous substance.
    NMR (CDC1,) -. 0.92 (6H, ha, ° (CH ,,, - CH -) -, 1.1-1.9 (12H, t, (CH3) C- -CHi-CH -); 2.28-2; , 52 (4H, t,
    CON
    .sig-ns
    CH.2-CHT.
    I M-3,30-3, 72 (6H, 25
    / СН-2.- СНО.
    t, -CH, Ar, -CO N, 52
    CH, -CH.2
    (1H, t, -NH-CH-CO-);. 3.20 (1H, t, -NH) i 7.20 (5H, S, aromatic protons).
    Similarly, 10.7 g (94%) of 4-benzyl-1-L-leucylpiperazine hydrochloride are obtained, starting from 12.3 g of tert-butyl ether (3) -1- (4-benzylpipe rasin-1-ylcarbonyl) -3 -methylbutylcarbamic acid,
    A small amount of this product was treated with two equivalents of triethylamine to obtain the corresponding base, which, as determined by NMR spectroscopic analysis, was 4-benzIl-1-L-leucylpiperazine.
    NMR (CDCl1), 0.94 (6H, d, I-7Hz, (CH) CH-); 1.36 (2H, t, -);
    1.90 (W, t, -SNg-bn-); 2.16-2.68
    (6H, t, -NH. ,, -С01Я
    , UNSNG-SN
    4.00 (7H, m,
    , ct /
    ,
    Shg-SNg
    /
    ; N-CHjAr, -NH-CH-CO-), 7.44 (5H, s, aromatic protons).
    The condensation reaction of 4.03 g of mono-ethyl-trans-epoxy-succinate and 9.12 g of 4-benzyl-1-b-leucylpiperazine dihydrochloride is carried out in the same way as the ethyl-trans-3-t (S) -1-1 (4-diphenyl -methyl piperazin-1-ylcarbonyl) -3-methyl butylcarbamoyl - α-oxiran-2-carboxylate, resulting in 6.89 g of ethyl trans-3- (5) -1- (4-benzylpiperazin-1-ylcarbonyl) - 3-methyl butylcarbamoyl-α-oxirane-2-carboxylate as a light yellow amorphous substance (yield 63%).
    IR spectrum (free of impurities): 1755, 1690, 1640, 900 cm-.
    NMR (CDCl); 0.92 (6H, ha, (CH,), CH-); 1.1-1.7 (6H, t, -CT-,); 2.38 (4H, t,
    SNTGSHO
    -C0, 3-3.7 (8H,
    CH-CH2
    t
    X
    CIS2-CH2.
    Coolant - - CH 2-CH2
     - tCHjAr
    -sn-sn35 40
    45
    z;
    °
    55
    T
    4, 15 (2H, d, 1 7H2, ,, CH3) 4.82 (1H, t, -CH-CH-CO-); 6.5-6.9 (W, t, -Sh) 5 7.12 (5H, S, aromatic protons).
    Starting from 6.38 g of ethyl trans-3- - (S) -1- (4-benzylpiperazin-1-ylcarbonyl) -3-methylbutylcarbamoyl -ocorane-2-carboxylate, was prepared as in Example 1-6, 25 g (99%) sodium ,. -trans-3- (S) -1- (4-benzylpyrazin-1 - -ylcarbonyl -) - 3-methylbutylcarbamoyl | - -oxyrane-2-carboxylate.
    Example 3, a condensation reaction of 7.47 g of tert-butoxycarbonyl-L-α-leucine monohydrate and 6.18 g of 1 (4-methoxyphenylmethyl) piperazine was carried out as described in Example 1, noi.-v-oh 12.0 (95 %) tert-butyl ether (S) (4-methoxyphenylmethyl) - -piperazin-1-ylcarbonyl-3-methylbutylcarbamic acid as a colorless amorphous substance, from which 11.2 g of lL-leucyl-4- (4 -methoxyphenylmethyl) -piperazine dihydrochloride.
    As in Example 1, a condensation reaction is carried out with 4.8 g of monoethyl-trans-epoxy succinate and 11.2 g. 17
    - L-leucyl-4- (4-methoxyphenylmethyl) - -piperazine dihydrochloride, resulting in 5.0 g (38%) ethyl-trans-3- (8) -1- (4- / 4) as a colorless amorphous substance. -methoxyphe nylmethyl / -piperazin-1-ylcarbonyl) -3-methylbutylcarbamoyl -oxyran-2-carboxylate.
    JQ-spectrum (KVg): 1750, 1630, 900 cm
    Mass spectrum (t / e): 461 (M-), 318 J21 (100%).
    From 5.0 g of ethyl trans-3- (5) -1- (4- - / 4-methoxyphenylmethyl) -piperazin--1-ylcarbonyl) -3-methylbutylcarbamoyl-oxirane-2-carboxylate, 4 , 8 g (97%) sodium trans-3- (5) -1- (4- (4-methoxyphenylmethyl) - piperazin-1-ylcarbonyl) -3-methyl-carbamoyl 1-oxirane-2-carb6-xylate as white powder.
    IR spectrum (KVg): 1630, 900 cm.
    NMR (CDjOD): 0.94 (6H, d, (CHj) jCH -), - 1.6 (3N, m, -CHj-CH-);
    2.46 (4H, t,
    .-)
    CH2 - CH2
    /
    X
    3.3-3.7 (8H, m, -CONCH, -CH,
    ,
    c -ocii) i -CH-CH-
    (1H, m. -N-CH-CO-); 6.94 (2H, d,
    L
    IVOCH. -
    MAIN
    Example 4. While cooling with ice, 30 ml of a methylene chloride solution of 41.2 g of N, N -dicyclohexylcarbodiimide are added dropwise to 70 ml of a methylene chloride solution of 4.98 g of tert-butoxycarbonyl-b-leucine monohydrate and 2.30 g of N -oxysuccinimide, the mixture is stirred at room temperature for 4 hours. Then, again while cooling with ice, 6.79 g of 1- (2,3,4-trimethoxyphenylmethyl) piperazine dihydro is added dropwise to the mixture
    0
    50
    61. eight
    chloride and 8.5 N01 triethylamine. The mixture is then stirred overnight at room temperature. After removal of the methylene chloride by distillation under reduced pressure, ethyl acetate is added to the residue and the reaction mixture is filtered. The filtrate is first washed with an aqueous solution of sodium bicarbonate and then with an aqueous saturated solution of sodium chloride, dried over sodium sulfate, p &amp; Solvent is distilled off in vacuo. The oily-viscous product obtained is purified by chromatography on a column of silica gel (the development solvent is a mixture of chloroform and methanol in a ratio of 20: 1). 9.5 g (99%) of (5) -3-methyl-1-C4- (2,3,4- -trimethoxyphenylmethyl) -piperazin-1- -ylcarbonyl-butylcarbamic acid are obtained as colorless. viscous matter
    NMR CCDClp, c /: 0.92 (6H, t,
    5 (CHj) CH-); 1.13-1.84 (12H,
    m.
    (CH3) C C-, -CRi-CH-); 2.30-2.60 (4H, m.
    -CON
    /,
    Shg-CH-2
    CH2-Sh2
    /
    : N -), 24-3.68 (6H, m,
    -CON
    С% -СНг. CH2-CH2
     1 -CH2Ag) s, 84 (9n,

    t, Ar-OCHjX 3); 4.56 (1H, m, —N — CH — —CO—); 5.24 (1H, t, -CONH-); 6.56 (1H, d, aromatic protons) -; 6.90 (1H, d, aromatic protons).
    Under ice-cooling, a stream of hydrogen chloride gas is passed into 200 ml of ethyl acetate to obtain an all-saturated solution, to which is further added 50 ml of an ethyl acetate solution of 9.5 g of tert-butyl ether (8) -3-methyl-1-4- (2.3 , 4-trimethoxy-phenylmethyl) -piperazin-1-ylcarbonyl-butylcarbamic acid. This mixture was stirred at room temperature for 2 hours. Ethyl acetate and excess hydrogen chloride were removed by distillation under reduced pressure. 8.6 g (95%) of 1-b-leucyl-4- - (2,3,4-trimethoxyphenylmethyl) -piprazine dihydrochloride are obtained in the form of light yellow crystals.
    A small amount of this product was treated with two equivalents of triethylamine to give the free base, which, as it was, was established by NMR spectral analysis, was 1-L- -Lyutsh-4- (2,3,4-trimetoxyphenyl-methyl) -pipervain .
    NMR (CDCl 3): 0.93 (6H, d, .5Hz, (CH3) 2CH-); 1.35 (2H, ha, -CHj, -CH-); 1.90 (1H, ha, -CHN-CH-); 2.43 (4H, t.
    - SOK / - 1 - 3, d-s.7
    /
    ,, CH2, -CH.
    (6H,
    .,. ... / -CH2-; 3.84
    -CONC - CH.1
    S, Ar-OS1TShZ); 3.93-4.23 (3N, t, NHJ-CH-) i 6.57 (W, d, aromatic protons), 6.93 (1H, d, aromatic protons).
    After cooling with ice, 10 ml of a methylene chloride solution of 1.60 g of N, N-dicyclohexylcarbodiimide is added dropwise to 20 ml of a methylene chloride solution containing 1.24 g of monoethyltransepoxysuccinate and 0.89 g of N-oxysuccinimide, followed by a mixture Stir at room temperature for 4 hours. Then re-cooling with ice to a mixture of
    3.52 g of 1-b-leidyl-4- (2,3, 4-trimethoxyphenylmethyl) piperazine dihydrochloride is added, then 4.4 ml of triethylamine is added to it and the reaction mixture is stirred overnight at room temperature. After the oud
    laziness of methylene chloride by distillation
    ethyl acetate is added under reduced pressure, and the insoluble Shys is filtered off. The filtrate is first washed with an aqueous solution of sodium bicarbonate and then with an aqueous saturated solution of sodium chloride, dried over sodium sulfate and the solvent is removed by distillation under reduced pressure. 4 g of an oily orange substance are obtained, which is purified by chromatography on a column of silica gel (the development solvent is a mixture of chloroform and methanol in a 50: 1 ratio). Then, 3.05 g (75.3%) of ethyl trans-3- (5) -3-methyl-1- (4- [2,3,4-trimethoxyphenylmethyl] -piperzin-1-ShIcarbonyl) is isolated. -butylcarbamoylJ-oxiran-2-carboxylate as
    W
    ,
    15
    20
    thirty
    ,
    16110
    colorless oily viscous substance.
    M (t / e): 322 (), 181 (100%).
    Under ice cooling to a 20 ml of ethanol solution, 2.38 g of ethyl trans-3-1 (5) -3-methyl-1- (4- [2,3,4-trimethoxy-diphenylmethyl] -piperazin-1 -ylcarbonyl) -butylcarbamoyl -oxyran-2-carboxylate, 9.48 ml 0.48 n. a solution of sodium hydroxide in ethanol, after which the mixture is stirred for 2.5 hours at room temperature. After the ethanol is removed by distillation under reduced pressure, water is added, the undissolved residue is filtered using Sellaite. The filtrate is evaporated and dried under reduced pressure to give 2.31 g (98%) of sodium nitride-trans-3- (5) -3-methyl-1- (4- [2,3,4-trimetok-syphenylmethyl] - piperazin-1-ylcarbonyl) - -butylcarbamoyl-oxyran-2-carboxylate in the form of a light yellow powder.
    IR spectrum (KVg): 1620, 1390, 900 cm-.
    NMR (SVzOV): 0.92 (6H, d, 1 7H20t (CH3) gCH-); 1.3-1.7 (3N, m, -CHi-CH-).
    2.4 (4H, m, —CON K-); 3.2-3.6 (8H, w,
    . CON / N SNg-CH2
    CH i-. / 0
    -GH-III-;
    0
    y d 5
    3.74D9N, t, Ar-OSSNZhZ); 4.8 (1H / t, -N-CH-CO-); 6.60 (1H, d, aromatic proton), 6.88 (1H, d, aromatic proton) 8.04 (1H, t, -HNCO-) (in DMSO-D).
    The sodium salt thus obtained was added to an equivalent amount of 0.1 n. hydrochloric acid and the mixture is evaporated to half the original volume. The precipitated white crystals are filtered off, washed first with cold water and then with ethanol and dried under reduced pressure. The corresponding melting point free acid is obtained. 190-192 with (with decomposition).
    IR spectrum (KVg): 1650, 900. Calculated,%: C 33.41; H 7.15, N 8.51.

    Found,%: C 58.37; H 7.23N 8.40.
    11131816112
    EXAMPLE 5: Condensation is carried out. Example 6. 7.47 g of tert-butoxycarbonylsation is carried out to 7.47 g of tert-butoxycarbonyl-L-leucine monohydrate and 3.42 g of 1-ethyl-gshperaein as in Example 1. 6.4 g (65%) of (S) -1 - (4-ethylpiper.azin-1 -ylcarbonyl) -3 methylbutylcarbamic acid tert-butyl ester is obtained in the form of a colorless viscous liquid,
    NMR (CDClp ,, 0.88 (ЗН, d, (CHj) CH-); 0.94 (ЗН,, d, (CH) СН-); 1.04 (ЗН, t,, -NCHjCHj); t , 38
    (9H, s, (ClbbC-); 1.3-1.8 (3H, m, -CH2-CH-); 2.30 (6H, m.
    CH j
    CH.2,
    p. N-CH2-; 3.40 (4H, m
    , 4.4oOH,
    sn-sng, in
    t -CON
    CH 2
    .K-) p, 08 (2H,
    1I -): 4.54 (W, t.
    -Sh-CH-CO-); 5.10 (1H, bp, -NH-).
    Analogously to Example 1, 6.0 g (100%) of 4-ethyl-1-b-leucylpipe-5 d, -NCHXH) are obtained; 3.54 (4H, razine dihydrochloride in the form of, white crystals.
    3.13 g of monoethyl trans epoxysuccinate and 6.0 g of 4-ethyl-1-b-leucylpiperazine dihydro-sh-b-CO-CO) are condensed; 5.28 (1H, LP, -NH); chloride, as described in Example 1, is obtained 5.9 g (82%) of ethyl trans-3- (S) -1- (4-ethylpiperazin-1-ylcarbonyl) -3-methyl butylcarbamoyl} -oxite.
    .SN.O SNO -CONC- /
    cn-sn
    wound-2-carboxylate as a light yellow amorphous substance,
    M (t / e): 369 (M), 228, 113, 84 (100%),
    As in Example 1, from 5.9 g ethyl 35
    6.10 (1H, dt,, 7H7, -CHjCH CH-); .6.42 (1H, d, -CHH-Ar); 7.2 (5H, m, aromatic proton).
    As described in Example 1, 10.0 g of 4-cyanamyl-1-leucylpiperazine dihydrochloride are obtained in the form of light yellow crystals starting from 10.7 g of tert-butyl ether (8) -1- (4-zinc). -trans-3-C (S) -1- (4-ethylpiperazin-1-namylpiperazin-1-ylcarbonyl) -3-me- -ylcarbonyl) -3-methylbutylcarbamoyl-tylcarbamic acid, -oxyran-2-carboxyl 1 get a condensation reaction 10.0 g of 4-zinc, 5.1 g (88%) sodium trans-3-C (3) -1-namyl-1-b-leucylpiperazine dihydrochlo- - (4-ethylpiperazin-1-ylcarbonsh1) -3 - p and 4.13 g of monoethyl trans-epoxy-methylbutylcarbamo-1-oxirane-2-karsuccinate is carried out in a manner similar to Example 1, this results in 8.1 g (69%) of ethyl trans-3 (3) -1- (4-cinnamylpiperazin-1-ylcarbonyl) -3-methylbutylcarbamoyl-oxirane-2-carboxylate in 50 as a light yellow amorphous substance,
    IR spectrum (KBG): 1750, 1630 cm. As in Example 1, from 8.0 g of ethyl trans-3- (3) -1- (4-55-cinnamylpiperazin-1-ylcarbonyl) -3- - MethylbyteshIkarbamoylJ-oksiran-2-kap-
    bauxilate as a white powder, IR spectrum (KBr): 1620, 900 cm-NMR (SVBOV), 0.96. (CH, d, (CH3) iCH-); 1.12 (3N, t,,); 1.6 (3N, m, -CH-); 2.5 (6H, m,
    BUT CH.TV -CON -
    CH7.-SNg |

    CH2
    (6H, in, -CO N
    -4.9. . (1H, m, -NH-CH-CO-),
    NL
     / ,. of boxylate, 7.6 g (96%) of sodium — g of CH2, —CH — CH. - trans-3- (5) - (4-cinnamylpiperazin-1-ylcarbonyl) -3-methylbutylcarbamoyl fO
    . Α-L-leucine monohydrate and 6.06 g of 1-cinnamylpiperazine, as in Example 1, 5, 10.7 g (86%) of tert-butyl ether (8) -1- (4-cinamylpiperazin-1-ylcarbonyl) are obtained. ) -3-methylbutylcarbamic acid as a colorless amorphous substance. NMR (CDCl,), /: 0.88 (3N, d,
    ) / 0 z «СН
    sh
    .CH: i-CH- i 1.42 (9H, S, (CH, a) sS-);
    Shz
    1.3-1.9 (ЗН, t, -), 2.44 (4H,
    15
    0
    t -CON
    ,
    CH 2
    .K-) p, 08 (2H,
    5 d, -NCHXH); 3.54 (4H,
    t.
    1I -): 4.54 (W,
    ,, -NCHXH); 3.54 (4H,
    —bn-CO-); 5.28 (1H, LP, -NH); .SN.O SNO -CONC- /
    cn-sn
     3
    α-oxirane-2-carboxyl ata as a pale yellow powder.
    IR spectrum (KVg): 1620, 890
    NMR (SVB), /: 0.94 (6H, (CH3) iCH-)}. 1.4-1.7 (3H, -CHt-CH-); 2.48 (4H, ha,
    -CON- -
    CH7.-CH /
    -NCH, jCH); 3.2 - 3.6
    juice / 52-cis
    -N-) 3.12 (2H, d,
    m.
    (6H, J; 4.8 (1H,
     X -ciJ (j.
    m, —NH — CH — CO—); 6.12 (1H, dt, bNg t / Hz, -CHj-CH CH-); 6.48 (1H, d, I-16HZ, -CH CH-Ar); 7.1-7.3 (5H, m, aromatic protons).
    Example 7. While cooling with ice, 40 ml of an ethyl acetate solution of 10.3 g of N, N — dicyclohexylcarbodiimide are added dropwise to 150 ml of an ethyl acetate solution of 12.5 g of tert-bu-2950, 1635, 770, 725 cm. toxycarbonyl-b-leucine monohydrate and NMR (CBC1e), s /: 0.96 (6H, m
    20, the solvent is removed by distillation under reduced pressure. This gives .9.16 g (78%) of 1-b-leucyl-4- (2-pyridyl) -piperazine.
    IR (without impurities): 3350,
    5.76 g of N-oxysuccinimide, after which the mixture is stirred at room temperature for 3 hours. With re-cooling with ice, 8.16 g of 0 1- (2-pyridyl) piperazine are added and the mixture is stirred overnight at room temperature. Then the precipitate is filtered off. The filtrate is washed first with an aqueous solution of sodium carbonate, then with a saturated solution of sodium chloride, dried over sodium sulfate, and the solvent is distilled off under reduced pressure. Received by
    40
    JL4.J.V - - - -L3 / -. V VJlljIII l
    (CHj) CH-); 1.4 (3N, m,); 7T2H, br, —NHi); 3.64 (9H,
    ha
    -CON
      -NH OT-CO-);
    FROM T from T
    CH2 - CH {
    6.68-8, 20 (4H, t, and rheumatic protons.
    Under ice-cooling, a 10 ml ethyl acetate solution of 3.90 g of N, N-dicyclohexylcarbodiimide is added dropwise to a 75 ml of ethyl acetate solution of 3.03 g of mono-ethyl trans-epoxy succinate and 2.18 g of N-oxysuccinimide and the resulting mixture was stirred at room temperature overnight. Upon re-cooling with ice, the residue was purified by chromatography on a column of silica gel (the development solvent was methylene chloride and methanol in a ratio of
    10: 1) 16.1 g (85.6%) of tert-bavl 10 ml were isolated: ethyl acetate solution-butyl- (8) -3-methyl-1-14- (2-pyridyl) - -. , / „H -piperazin-1-ylcarbonyl-butylcarbamate.
    IR spectrum (without impurities): 1710, 1640, 1600, 775, 730.
    tt in,
    aqueous sodium bicarbonate solution, and then aqueous saturated solution of sodium chloride, dried over sodium sulfate, the solvent is removed in vacuum g. - Next, the resulting NMR reaction (CDCli) X: 0.96 (6H, t, (CHi) iCH- ); 1.46 (9H, s, (CHjljC-), 1.4-1.8 (3H, m, -CHi-CH-); 3.64 (8H, m,
    Cho-cho. -CON-
    pa 5,22 H. 1-b-lecyl-4- (2-pyridyl) - -piperazine and the whole mixture is stirred at room temperature overnight. The precipitate is removed by filtering by CQ and the filtrate is washed first.
    og , 65 (1H, t.
    TNG-SN-G,
    —NH — CH — CO—); 5.28 (III, Lg, -NHCO-); 6.62-8.08 (4H, w, aromatic protons).
    The remaining residue is purified by chromatography on a column of silica gel (eluent is ethyl acetate). 7.01 g (92.0%) of ethyl trans-34 were isolated.
    2950, 1635, 770, 725 cm. NMR (CBC1e), s /: 0.96 (6H, m
    Under ice cooling, a stream of gaseous hydrogen chloride is passed through 200 ml of ethyl acetate.
    To the resulting saturated solution was added 16.0 g of tert-butyl- (5) -3-methyl-1-4- (2-pyridine1) piperazine-1-ylcarbonyl-butylcarbamate. The mixture is stirred for 30 minutes. The solvent and hydrogen chloride were removed by distillation under reduced pressure, and 200 ml of water was added to the white powder thus obtained to dissolve the powder in it. After washing with ethyl acetate, an aqueous solution of sodium bicarbonate was added to pH 8 and sodium chloride, after which the solution was extracted with ethyl acetate (3 x 100 ml). After drying over sodium sulfate, the solvent is removed by distillation under reduced pressure. This gives .9.16 g (78%) of 1-b-leucyl-4- (2-pyridyl) -piperazine.
    IR (without impurities): 3350,
    2950, 1635, 770, 725 cm. NMR (CBC1e), s /: 0.96 (6H,
    JL4.J.V - - - -L3 / -. V vjllj
    (CHj) CH-); 1.4 (3N, m, br, -NHi); 3.64 (9H,
    -CON

    FROM T from T
    CH2 - CH {
    6.68-8, 20 (4H, t, and rheumatic protons.
    Under ice-cooling, a 10 ml ethyl acetate solution of 3.90 g of N, N-dicyclohexylcarbodiimide is added dropwise to a 75 ml of ethyl acetate solution of 3.03 g of mono-ethyl trans-epoxy succinate and 2.18 g of N-oxysuccinimide and the resulting mixture was stirred at room temperature overnight. While being re-cooled with ice, 10 ml of an ethyl acetate solution was added. , / „H
    Bavl 10 ml: ethyl acetate solution. , / „H
    ,
    an aqueous solution of sodium bicarbonate, and then aqueous solution of sodium chloride, dried over sodium sulfate, the solvent is removed in vacuo. Next, the reaction is obtained 5,22 H. 1-b-lecyl-4- (2-pyridyl) - - piperazine and the whole mixture is stirred at room temperature overnight. The precipitate is removed by filtration and the filtrate is washed first.
    aqueous sodium bicarbonate solution, and then aqueous saturated sodium chloride solution, dried over sodium sulfate, the solvent is removed in vacuo. Next, the resulting reaction residue is purified by chromatography in a silica gel column (ethyl acetate solvent). 7.01 g (92.0%) of ethyl trans-155 are recovered.
    -t (S) -3-methyl-1- (4- / 2-pyridyl / -PI-perazin 1-ylcarbonyl) -butylcarbamoyl-oxyran-2-carboxylate as a light yellow substance
    IR spectrum (KVg): 1740, 1640, 900 770 cm.
    NMR (CDClI), t /: 0.96 (6H, hectare, (CIUHCH-); 1.34 (3N, t,, -CO CHNCH-4) 1.6 (3N, t, -CHi-CH-) ; 3


    3.74 (10H, t, -CO-1I
    .Pcs-GH 2.4
    CH2-W {
    / x), 4.24 (2H, t, -CO SI ,, -);
    -CHI-CH 5, 08 (1H, t, -NH-CH-CO-) 6.68, 7.18 7.62. and 8.30 (5H, t, -NHCO-, aromatic protons).
    As described in Example 1, 6.8 g (100%) of trans-3-t (S) -1- are obtained from 6.70 g of eTyl-trans-3- (S) -methylcapromoyl-J-oxy-2-carboxylate. - (4- / 2-pyridyl / -piperipazin-1-ylcarbo-NIL) -3-methylbutylcarbamoyl-hydroxy-sodium-2-carboxylate sodium in the form of a light yellow powder.
    IR spectrum (KVg): 1660-1590, 300, 770 cm-,
    Example 8. A condensation reaction of 12.5 g of tert-butoxycarbonyl-L-leucine monohydrate and 8.21 g of 1- (2-pyrimidinyl) piperazine was carried out in the same manner as described in example 7, 13.4 g (71%) of tert-1 were obtained. butyl- - (8) -3-metsh1-1 (4- / 2-PYRIMIDINIL / - -piperazin-1-ylcarbonyl) -butyl-carbamate,
    IR spectrum (KVg): 1710, 1630, 1590 800 cm
    NMR (CDCl,), c /: 1.00 (6H,
    t.
    (Cl) 2CH-); 1.5 (9H, S (CHa) sS-); 1.4-1.8 (3N, t, —CHi — CH .—); 4.0 (8H, t,
    CHQ-CHi. CO-Nf-- -
    CH-i-CH
    X
    -N--); 4.84-5.47
    (2H, Pr, -CONH-, -NH-CH-CO-); 6.8- 8.68 (ЗН, t, aromatic protons).
    As described in Example 7, out of 13.3 g of tert-butyl- (S) -3-methyl-1- (4- (2-pyrimidinyl) -piperazin-1-ylcarbonyl) -butylcarbamate, and 9.76 are obtained. g (100%) of 1-b-leucyl-4- (2-pyrimidinyl) - -piperazine.
    IR spectrum (KBG): 2960-2940, 1630, 1590, 800 cm-.
    6116
    NMR (CDCl1): 0.99 (6H, ha, (CH3) iCH-); 1.4 (3N, t); 1.70 (2H, t, Shb-); 3.92 (9H, t,
    /
    СНтгСНт ,,
    /
    -
    56
    ten
    15
    20

    ,

    ,
    thirty
    35
    40

    45
    6.75, 8.59 (3N, m, aromatic protons).
    A condensation reaction of 3.52 g of mono-ethyl trans-epoxysuccinate and 6.10 g of 1-b-leucyl-4- (2-pyrimidinyl) -piprazine is carried out in the same manner as described in Example 7, to obtain 8.50 g (9 ., 1%) ethyl trans-3- (8) -3-methyl--1- (4- [2-pyrimidinyl] -piperazine-1- -ylcarbonyl) -butylcarbamoyl-1-oxyrane-2-carboxylate.
    As described in Example 7, from 8.00 g of ethyl trans-3-C (8) -3-methyl--1- (4- [2-pyrimidinyl] -piperazin-1 -ylcarbonyl) -butylcarbamoyl-hydroxy ran-2-carboxylate get 7.60 g of sodium-trans-3- T (5) -3-methyl-1- (4- / 2-pyrimidinyl / -piperazin-1-ylcarbonyl) -butyl carbamoyl-oxirane -2-Carboxylate as a light yellow powder.
    IR spectrum (KVg): 1680-1600, 1580, 900 and 800 cm-.
    The resulting sodium salt (518 mg) is neutralized by adding an equivalent amount of 0.1 n. hydrochloric acid, and then subjected to extraction treatment with ethyl acetate. The prepared extract solution is dried over magnesium sulfate and the solvent is removed by distillation. 449 mg (92%) of the corresponding free acid are obtained in the form of white crystals with a melting point of 83, (with decomposition).
    IR spectrum (KVg): 1740, 1630, 1590, 900, 800 cm-.
    NMR (CDCl1), o: 0.96 (6H, t, (CH3) aCH-); 1.54 (3N, m, -CnjCH-);, 3.68
    lS5
    X
    .СЩ-СНг
    SNT-ShTG
    4.96 (1H, t, -NHCHCO-); 6.46, 8.10 (3N, t, aromatic protons); 7.24 (1H, t, -NHCO-); 9.90 (W, Lg, -CO2N).
    Mass spectrum (w / e): 391 (M), 347, 122, 86- (100%).
    Calculated,%: C 55.23; H 6.44, N 17.89.
    17
    S1 "m L
    Found,%: C 55.01; H 6.51;
    N 17.62.
    Example 9. While stirring and cooling with ice, 100 ml of an ethanolic solution of potassium hydroxide was added dropwise to 100 ml of an ethanol solution of 18.8 g of diethyl- (2K, 3K) -epoxy succinate. This solution is stirred overnight and cooled with ice. The precipitate is filtered off, washed with cold ethanol, and then dried under reduced pressure to obtain 16.0 g of potassium-monoethyl- (2E, 3K) - -epoxysuccinate (yield 81%).
    (o1) in -86.4 (C-1, VDE).
    15.0 g of potassium-monoethyl- (2E, 3K) - -epoxysuccinate is dissolved in an aqueous solution of sodium chloride (75 ml) with stirring while cooling with ice, after which 7.6 ml of concentrated hydrochloric acid is added. This solution was subjected to ecstatic treatment with 100 ml of ethyl acetate, washed with an aqueous saturated solution of sodium chloride and filtered through a glass filter with magnesium sulfate placed on its surface, after which it was poured into a reaction vessel, into which 8.7 g of H-oxysuccinium ida was placed. . While stirring and cooling with ice at a temperature not exceeding 15 ° C, 60 ml of an ethyl acetate solution, 15.6 g of N, N -dicyclohexylcarbodiimide are added dropwise and the mixture is stirred at room temperature for 2 hours. After this, ethyl acetate is added dropwise a solution of 28.7 g of 1-1 -, - leucyl-4- (2,3,4-trimethoxyphenylmethyl) piperazine and the mixture is stirred overnight at room temperature. The reaction solution is further cooled with ice and the precipitate is removed by filtration. The filtrate is washed with an aqueous solution of sodium bicarbonate and an aqueous saturated solution of sodium chloride, dried over magnesium sulfate, and then the solvent is distilled off under reduced pressure. The resulting yellow oily viscous product is subjected to chromatographic purification in a column with silica gel (solvent for the developer is chloroform in a mixture with methanol in a ratio of 50: 1). 29.6 g (75%) of ethn1- (2N, 3R) -3-i (S) -3-metsh1-1- (4- / 2,3,4-trime1318161
    18
    five
    0
    five
    toxphenylmethyl (-piperazin-1-ylcarbonyl) -butylcarbamoyl -oxyran-2-carboxylate as a colorless oily substance.
      -51.9 (0 - 1.0, ethanol).
    26.8 ml. 1 n. sulfuric acid is added to a 50 ml diethyl ether solution of 14.0 g of ethyl- (2E, 3R) -3- (S) -3-methyl-1- (4- [2,3,4-trymethoxyphenylmethyl] -). piperazin-1-ylcarbonyl) -butylcarbamoyl-oxirane-2-carboxylate and the mixture is stirred. Thereafter, the aqueous layer is separated and distilled under reduced pressure. 15.0 g (98%) ethyl (2R, 3K) - (3) -3- -methyl-1- (4- / 2,3,4-trimethoxyphene-methyl / -piperazin-1-yl) -carbonylb are obtained. - tilcarbamoyl 3-oxirane-2-carboxyl 1 semisulphate in the form of colorless crystals.
    IR (KBG): 1745, 1645, 895 cm-1.
    NMR (DMSO-dfe + DjO): 0.90 (6H, m, (CH3); CH-); 1.22 (3N, t, -COj CH); 1.3-1.75 (3N, m, -CE.fH-)
    2.6-3.0 (4H, m
    .
    .-CO-N :: -) CH2CHf
    ).
    thirty
    .j 3.2-3.9 (17H, m,
    / H
    sn-snSNZO OSNz
    DOS
    0
    five
    0
    five
    4.07 (2H, q, -COjCH -); 4.62 (1H, t, -NnCHCO-) j 6.62 (1H, d, aromatic proton); 6.92 (1H, d, aromatic proton); 8.52 (W, d, ,, -NHCO-).
    (c) d -42.0 (C - 1.0, 1 N. sulfuric acid).
    When cooled by ice 55.6 ml 0.48 n. a solution of sodium hydroxide and ethanol is added to 100 ml of ethanolic solution 14.0 g of ethyl- (2R, 3R) -3- (8) -3-methyl-1- (4- [2,3], 4trimethoxyphenylmethyl] -piperazine - -1-ylcarbonyl) -butylcarbamoyl -oxy-3-carboxylate and the mixture is stirred at room temperature for 2.5 hours. The ethanol is removed by distillation under reduced pressure and water is added. The undissolved residue is filtered, the filtrate is concentrated and dried under reduced pressure.
     19131816
    13.5 g (98%), sodium- (2K, 3R) -3- (5) -3-methyl-1- (4- [2,3,4-trimethoxyphenyl] -piperazine- 1-yl-carbonyl) -butylcarbamoyl-1-oxirane-2-carboxylate as a pale yellow powder. ,
    IR spectrum KBG): 1620, 900 cm-.
    NMR (DMCO-d), cf:, 0.90 (6H, t, (CH}) iCH); 1.30-1.70 (3N, ha, -CH, CH-);
    ten
    SI SNT.
    2, d5 (4n, m, -co-N (;: TSSi3, ooSngSng
    3.70 (8H, ™ ,.
    sn ss / o
    ) 0.
    SNCH
    , 76 (9H, t,
    CH-xO OSI;
    4.70 (1H, t, -NHCH-CO-); 6.64 (W, d, aromatic proton); 6.88 (1H, d, .j, aromatic proton); 8.08 (1H, d, -NHCO-).
    2 ml of an acetone solution of 0.25 g of oxalic acid dihydrate are added to 6 ml of an acetone solution of 1.04 ethyl- (2K, 3R) -3- | (5) -3-methyl-T- (4- - / 2.3 , 4-trimethoxyphenylmethyl-1-piperazin-1-ylcarbonyl) -butylcarbamoylJ-oxirane-2-carboxylate 5 the precipitated crystals are filtered and dried. Obtain 0.99 g (81%) of ethyl- (2K, 3K) -3- (5) -3-metsh1-1- (4- / 2,3,4-trimethoxyphenylmetsh1 / - -piperazin-1) oxalate -ylcarbonyl) -butylcarbamoyl-oxiran-2-carboxanate with a melting point of 132-133 ° C (with decomposition),
    (o /) j -37.6 ° (C - 0.99, water).
    Calculated,%: C, 54.98; H, 6.76; N 6.87.
    CjjH, NjO
    Found,%: C 54.80; H 6.87; N 6.89.
    Example 10. While cooling with ice and stirring 35 ml of an ethanol solution, 1.82 g of potassium hydroxide is added dropwise to 35 ml of an ethanol solution of 6.09 g of diethyl- (2S, 35) epoxysuccinate. The mixture is stirred overnight and cooled. The precipitation is filtered off, washed with cold ethanol and DIETSH10YME ether, and then dried, to obtain 4.55 g (71%) ka
    five
    0 Q
    five
    P
    120
    Lithium salt of monoethyl- (25, 38) -epoxysuccinate.
    (a) + 83.2 ° (C - 1, water) .4, 22 g of the potassium salt of mono-ethyl- (2S, 38) epoxy succinate is dissolved in 21 ml of an aqueous solution of sodium chloride while stirring and cooling with ice, after 2.14 ml of concentrated hydrochloric acid was added to the solution. The mixture was subjected to extraction treatment with 28 ml of ethyl acetate, the organic layer was washed with an aqueous saturated solution of sodium chloride, filtered through a glass filter with magnesium sulfate placed on its surface and placed in a reaction vessel into which 2.45 g of N- oxisuccinimide While cooling with ice and stirring, add 17 ml of ethyl acetate solution of N, N -dicyclohexylcarbodiimide, and the temperature should not exceed 15 seconds, and then stirred at room temperature for 2 hours. of added dropwise 17 ml of ethyl acetate rastvora- 8.07 g of 1-1-leucyl-4- (2,3,4-tri-methoxyphenylmethyl) piperazine and the mixture was stirred at room temperature overnight. Next, the reaction solution was cooled again with ice and the precipitated precipitate was removed by filtration. The filtrate is washed with an aqueous solution of sodium bicarbonate and a saturated solution of sodium chloride, dried over magnesium sulfate, then the solvent is evaporated under reduced pressure. The obtained yellow oil-like viscous product is subjected to chromatographic purification in a column of silica gel (the development solvent is a mixture of chloroform and methanol in a 50: 1 ratio), 7.40 g (67%) of ethyl- (28, 35) - methyl 1- (4- (2,3,4-trimethoxyphenylmethyl) -piperazin-1-ylcarbonyl) -butylcarbamoyl-oxirane-2-carboxylate.
    IR spectrum (KVg): 1755, 1685, 1630, 900 cm-.
    NMR (DMSO - dfc), 0.90 (6H, t, (CH3) iCH-); 0.08-1.80 (6H, m, -CHfH-, -COjCHjCH i); 2.38 (4H, m,
    -CQ-NC); 3.20-4.00 (17H, t ..

    CH-iCH
    /
    ,
     "- It r
    -coNC - --cvir- o
    CH CH -CH-CHCH O, CHoO
    -i - 22 (2H, q, I
    ChZ-osnz,
    m.
    ten
    15
    20
    7: 5H, -CO, CHj-); 4.84 (1H, -HCHCO-); 6.78 (1H, d, aromatic proton); 7.03 (1H, d, aromatic proton); 8.72 (1H, d,, -NHCH-),
    (oiy + 48.2 ° (C - 1.0, ethanol).
    6.13 ml of 1 n. sulfuric acid is added to a 11 ml diethyl ether solution of 3.20 g of ethyl- (25, 3S) -3-t (S) -3-methyl-1- (4- [2,3,4-trimethoxyphenylmethyl] -) piperazin-1-ylcarbonyl) - -butylcarbamoyl -oxyran-2-carboxylate, the mixture is stirred. Thereafter, the aqueous layer was separated and distilled under reduced pressure to obtain 3.32 g (95%) of ethyl- (2S, 35) -3- (8) -3-methyl-1- (4- / 2, semisulfate) 3, 4-trimethoxyphenylmembersh1 / -piperazin--1-ylcar6onyl) -butsh1carbamoyl -oxyran-2-carboxylate as a white powder.
    IR (KBG): 1745, 1645, 895 cm.
    NMR (DMSO - d +),.:: 0.88 (6H, m, (CH3) hCH-); 1.24 (3N, C, -COjCHjCHg); 1.3-1.75 (ЗН, t,); 2.6-3.0 (4H, t,
    thirty
    35
    CON
    h
    CON
    CH2 CH
    ) -, 3.2-3.9 (17H, m,
    40
    -N-CHgi 0

    LP Lrl
    OSS,
     -), 4.2A (2H, q,,
    45
    -CH2-CHf- NZO
    -Osn,
    WITH,); 4.84 (1H, m, -NHCHCO-); Q, 92 (1H, d, .j, aromatic roton) i 7.22 (1H, d, aromatic proton) j 8.84 (1H, d, I
    8E, -SCHSO-).
    (O) D +47, (C - 1.0, water).
    With ice cooling, 4.15 ml, 47 n. a solution of hydroxide nati in ethanol is added to 7.5 ml of a tanol solution of 1.04 g ethyl55
    ten
    15
    20
    16122
    - (2S, 35) -3-G (5) -3-metsh1-1- (4- / 2,3, 4-trime.oxyphenylmethyl / -piperazin-1-ylcarbonyl) -butylcarbamoyl -oxyran-2 the carboxylate, the mixture is stirred at room temperature for 2.5 hours. After the ethanol is removed by distillation, water is added under reduced pressure and the insoluble residue is filtered off. The filtrate is concentrated and dried under reduced pressure to obtain 1.00 g (97%) of sodium- (28, 35) -3- (8) -3-methyl-1- (4- - / 2,3,4-trimethoxyphenylmethyl / β-piperazin-1-ylcarbonyl) -butylcarbamoylJ-oxyran-2-carboxylate as a light yellow powder.
    IR spectrum (KVg): 1625, 895.
    NMR (DMCO-d,), d: 0.86 (6H, t, (CH3) hCH-); 1.20-1.70 (3N, ha, -CH2CH-);
    2.34 (6H, m, -C01lC 3, T-G
    3.60 (8H,
    ХН2СН2
    ™ -COЪ C -
    V / N-CH2-T CH 2Sh2 -
    /about
    CH-CH, 3.70 - 3.95 (9H,
    ha
    five
    0
    five
    Q
    five
    SNZO BAS.
    - W; ; , 75 (1H, t,
    .-Ш Н-СО-); 6.72 (1H, d,. Aromatic proton) 6.96 (1H, d, -, aromatic proton); 8.12 (1H, d, -NHCO-).
    (with /) р + 29, ZShS - 0,99, water).
    2 ml of acetone solution 0.25 g of oxalic acid dihydrate is added to 6 ml of acetone solution of ethyl- (2S, 35) -3- (8) -3-methyl-1- (4- / 2,3, 4-trimethoxyphenylmethyl (-piperazin-1- -ilka.rbonyl) -butylcarbamoyl -oxyran-2-carboxylate (1.04 g); precipitated crystals are filtered and dried, to obtain 1.03 g (84%) of ethyl oxalate (28 , 38) -3- (8) -3-methyl-1- (4- (2,3,4-trimethoxyphenylmethyl) -piperazin-1-ylcarbonyl) -butylcarbamoyl-oxirane-2-carboxylate with a melting point 132.5-133.5 ° C (with decomposition).
    (c) in -15 + 46.2S / 1.01, water).
    Calculated,%: C 54.98; H 6.76; N 6.87.
    23
    C4eH, N, 0
    1g
    Found,%: C 54.87; H 6.69; iN 6.76.
    Example 11. 6.5 g of epoxy succinic acid monoiobutyl ester is dissolved in 40 ml of ethyl acetate, then 4.0 g of N-OK-sysuccinimide is added to the solution. While stirring the mixture and cooling it with ice, 25 m of an ethyl acetate solution of 7.5 g of N, N - -dicyclohexylcarbodiimide are added dropwise to it, so that the temperature does not exceed 15 ° C. and then the mixture is stirred at room temperature for 2 hours. A 25 ethyl acetate solution of 13.1 g of 1-b-leuc-1-4- (2,3., 4-trimethoxyphenylmethyl) - -piperazine is added dropwise to the mixture and the resulting mixture is stirred at room temperature overnight. The reaction solution is cooled again with ice and the precipitated precipitate is filtered off. The filtrate is washed with an aqueous solution of sodium bicarbonate and an aqueous saturated solution of sodium chloride, dried over magnesium sulfate and the solvent is distilled off under reduced pressure to give a yellow oil-like viscous product. This product was subjected to purification by chromatography on a column of silica gel (the solution was a solvent: a mixture of chloroform and methanol in a 50: 1 ratio). 10.5 (55%) of iso-butyl-trans- (S) -3-methyl-1- (4- [2,3, 4-trimethoxyphenylmethyl] -piperazin--1-ylcarbonyl) butylcarbamoyl-hydroxyrane are obtained. -2-carboxylate as a light yellow oily substance.
    H11R (CDCl1): 0.84-1.04 (12H, m, -CHH4); 1.36-2.16 (4H, t, (CH5) CH-CH2. (CH) 2CH-CHj -0-); 2.40 cn CIS
    2.64 (4H, m,
    CH iCH j. 3.80 (8n, go, -CO1C N-CH sngsn / NN); 3.88-4; i2 (11H, t,, - OCH.
    5-OCH, 1-);
    SNZO
    s
    1816124
    5.04 (1H, t, -NH-CH-CO-) J 6.76 (1H, d, aromatic proton); 6.96 (1H, t, -NHCO -) - 7.12 (1H, d, aromatic proton).
    As described in Example 9, hemisulfate is obtained as a white powder.
    IR spectrum (KVg): 1750, 1645, 900 cm.
    PRI me R 12. As described in Example 9, from monoethyl- (2K, 3R) -epoxysuccinate and 1-L-leucyl-4- (2-pyrimidinyl) -piperazine, etch1- (2K, 3R) - (5) -3-methyl-1- (4- [2- pyrimidinyl] piperazine-1-Sh1carbo-, 5 nyl) butylcarbamoyl} -oxirane-2-carboxylate,
    (CO D -52 (C - 1.0, chloroform).
    Similar to that described in Example 9, ethyl- (2K, 3K) -3- (3) -3-methyl-1- (4- - [2,3,4-pyrimidinyl] -piperazin-1-ylcarbonyl) -butylcarbamoyl-oxyrane- 2- -carboxylate is subjected to hydrolysis with sodium hydroxide, the result is sodium- (2K, 3K) -3-DS) -3-methyl-1- (4- / 2-pyrimidyl / -piperazin-1--ylcarbonyl) -butylcarbamoyl -oxy-ran-2-carboxylate.
    -IR spectrum (Kvg): 1680-1600, 1590, 900 cm-.
    NMR (DMSO-dj), c /: 0.90 (6H, t, (CH,) CH-); 1.51 (ЗН, t,);
    / SNgSNt.
    3.04-3.12 (10H, t, -USHG
    20
    25
    thirty
    35

    .0.
    - puj; 4.83 (1H, m, -NHCBCO-); 6.67
    - SI (1H, t, aromatic proton) j 8.40 (3N, ha, aromatic proton, -NHCO-).
    (dL) J3 -44 ° (C 1.0, water).
    Example 13. As described in Example 9, ethyl- - (2S, 35) -3 is obtained from monostil- (25, 35) -epoxysuccinate and 1-L-leucyl-4- (2-pyrimidinyl) -piperazine. - (5) -3-methyl-1- (4- [2- pyrimidinyl] -piperazin-1-ylcarbonyl-butylcarbamoyl) -oxyran-2-carboxylate.
    (o) at + 78 ° (C - 1.0, chloroform).
    Analogously to Example 9, the methyl (28.38) - -3- (5) -3-methyl- (4- / 2-pyrimidinyl / - -piperazin-1-ylcarbonyl) -butylcarbamoyl-oxirane-2-carboxylate is subjected to hydrolysis sodium hydroxide, the result is sodium- (2S, 3S) -3- (5) -3-methyl-1- (4- / 2-pyrimidinyl / 2513
    -piperazin-1-ylcarbonyl) -butylcarbamyl-oxyran-2-carboxylate.
    IR spectrum (KVg): 1680-1600, 1580, 890 cm
    NMR (DMSO-dj), 0.91 (6H, t, (CH3) 1CH-); 1.51 (ЗН, t,);
    .CH7, CH7 ,. 3.05-4.06 (YUN, m, -CON
    / 0 CH2CHf
    -CH-CH-P, and -NHCHCG-);
    6.69 (W, m, aromatic proton); 8.29 (1H, d,., -NHCO-); 8.41 (2H, t, aromatic proton). (oi) j + 38 ° (C - 1.0, water).
    Example 14, 100 g of H- (trans--2,3-epoxy-3-ethoxycarbonylpropionyl) -1-leucine with this IR spectrum (KBr): 1730, 1650, 900 cm-- and the NMR spectrum (CDClI ): 0.98 (6H, t, (CH3) 2CH-); 1.32 (3N, t,, CHjCH O-); 1.68. (3H, m, -CH, CH-); 3.42-3.83 (2H, t, -CHCHH); 4.26 (2H, q,, CH3 CH, 0-) D 4.60 (1H, t, -NHCHCO-); 6.74 (, d,. ,, -NHCO-); 6.91 (0.5H, d, -NHCO-) 9.76 (1H, S, -СОН-) is dissolved in 15 ml of ethyl acetate, 0.421 g of N-oxysuccinimide is added to this solution, the resulting solution is cooled, 5 ml of an ethyl acetate solution of 0.754 g of N, N -dicyclohexylcarbodiimide are added dropwise. This mixture is further stirred for 3 hours at room temperature, then it is cooled again and 4.5 ml of an ethyl acetate solution of 0.974 g of trimetazidine are added dropwise to it. The mixture was stirred at room temperature overnight. This mixture is then cooled again and the undissolved residue is filtered off. The filtrate is washed with an aqueous solution of sodium bicarbonate and a saturated solution of sodium chloride, dried over sodium sulfate, and the solvent is removed by distillation in vacuo, to give a light yellow oil. This substance is subjected to chromatographic purification in a column with silica gel (the appearance solvent is a mixture of chloroform and methanol in a ratio of 50: 1). 1.7 g (89%) of ethyl- -trans-3- (S) -3-methyl-1- (4- (2,3,4-trimethoxyphenylmethyl) -piperazin-1 -ylcarbonyl) butylcarbamoyl is obtained. oxirane1 26
    -2-carboxylate - in the form of a colorless oily substance.
    Example 15. To 80 ml of an ethyl acetate solution 5.00 g of ethyl trans-3- f (S) -1-hydroxycarbonyl-3-methylbutylcarbamoyl-oxirane-2-carboxylate and 2.47 g of N-hydroxybenzotriazole with ice cooling 3.77 g of N, N -dicyclohexylcarbodiimide are added with stirring. The resulting mixture was stirred at room temperature for one hour. Then the reaction solution is cooled again with ice and 20 ml of an ethyl acetate solution of 3.00 g of 1- (2-pyrimidinyl) piperazine are added dropwise, and the temperature inside the reactor is kept below 5 ° C. The resulting solution is stirred. After completion of the reaction, the precipitate was removed by filtration. The resulting filtrate is first washed with an aqueous solution of sodium carbonate and then with a saturated aqueous solution of sodium chloride. Then, the filtrate thus washed was dried over anhydrous sodium sulfate and distilled under reduced pressure to remove the solvent, whereby a crude product was obtained. The substance obtained is purified on a chromatographic column with silica gel (a developing solvent is ethyl acetate). 5.52 g (72%) of ethyl trans-3-G (8) -3-methyl-1 - (4- (2-pyrimidinyl) -piperazin-1-yl-carbonyl) -butylcarbamoyl J-oxyrane are obtained. -2-carboxylate.
    The efficacy of compounds of Formula I against experimental myocardial infarction is determined; Male white rabbits weighing 2 kg were anesthetized by intravenous administration of 35 mg / kg sodium pentobarbital. Artificial respiration cuts were provided for each animal in the wall. The anterior descending artery was transferred to the dissection of approximately 7 mm downstream of the initial segment. After 24 hours, the heart was removed and the myocardium was cut between the apex of the heart and the 2 mmj thick section of the overwhelmed infarction areas were stained with a phosphorylase reaction, and the necrotic section was calculated using a planimetric method. Medicinal substances were injected 5 minutes before dressing (1/2 mg / kg intravenously), continuously after dressing for 2713
    1 h (T / 4 mg / kg / h, continuous addition) after 2 h after dressing (T / 8 mg / kg intravenously) and 3 h after dressing (T / 7 mg / kg intravenously ). Each compound was administered in the form of a physiological sodium chloride solution. In the case when the test substance differed poorly dissolve1 .28
    revenge, it was used in the form of salt. Only a physiological sodium chloride solution was administered to the animals of the control group (the total amount of the substance injected above the letter T).
    The results are presented in Table. one.
    Table 1
    29
    one
    2 4
    20
    8 7 8
    Verapamil hydrochloride (dissolved in physiological sodium-chloride solution)
    In tab. 1 shows the compounds:
    1-yatry-trans-3-C (3) -1 (4-diphenylmethyl-piperaen-1-Ilcarbonyl) -3-methylbutylcarbamoyl-oxirane-2-carboxylate;
    2 sodium trans-3- (3) -1- (zylpiperazin-1-Ilcarbonyl) -3-methNl-butylcarbamoyl-oxirane-2-carboxylate;
    3-sodium-trans-3- (3) - (4- (4-meth hydroxyphenylmethyl-1) -piperazin-1-ylcarbonyl) -3-methylbutylcarbamoyl-hydroxyran-2-carboxylate;
    4-sodium-trans-3- (3) -3-methyl--1- (4- (2,3,4-trimethoxyphenyl) -piperizin-1-sh1carbonyl) -butylcarbamoyl-β-oxirane-2-carboxylate;
    5-sodium-trans-3- (8) -1- (4-ethyl piperazin-1-Ilcarbonyl) -3-methylbutyl-carbamoyl-oxirane-2-carboxylate;
    6-sodium-trans-3- (3) -1- (4-cinnamylpiperazin-1-ylcarbonyl) -3-methyl butylcarbamoyl-oxyran-2-carboxylate;
    7-sodium-trans- (S) -1- (4- [2-pyridyl] -piperazin-1-ylcarbonyl) -3- -methylbutylcarbamoyl-oxirane-2-carboxylate;
    8-sodium-trans-3- (8) -3-methyl-1- (4- [2-pyrimidinyl] -piperazine-1 -ylcarbonyl) -butylcarbamost-oxirane-2-carboxylate;
    9-isobutyl-trans-3- (5) -3-methyl-1- (4- / 2,3,4-trimethoxyphenylme1318161 30
    Continued table. one

    6.2. 23.3 26.7
    ten
    11.0 ± 1.3
    2А.7
    Tyl / piperazin-1-ylcarbonyl) -butyl-carbamoyl-oxirane-2-carboxylate. hemisulfate;
    10-methyl-trans-3- (3) -3-methyl-1- (4- (2,3,4 trimethoxy phenylmethyl) α-piperazin-1-ylcarbonyl) -butylcarbamoyl-oxirane-2-carboxylate;
    11- ethyl- (2K, 3R) -3- (3) -3-methyl-1- (4-7253,4-trimethoxyphenylmethyl) -piperazin-1-ylcarbonyl) butylcarbamo-1-w-oxirane-2 -carb-oxyl;
    12, - ethyl- (23, 3S) -3- (8) -3-methy. P-1- (4-7253,4 trimethoxy phenylmethyl 7-piperazin-1-ylcarbonyl) -butylcarbamoyl-oxyran-2- carboxylate;
    13-sodium- (2K, 3K) -3- (3) -3-methyl-1- (4-72,3,4-trimethoxyphenylmethyl: l7-piperazin-1-ylcarbonyl) -butylcarbamoyl-oxyrane- 2-carboxylate;
    14-sodium (28, 3S) -3- (3) -3-methyl-1- (4-72,354-trimethoxyphenylmethyl 7-piperazin-1-ylcarbonyl) -butylcarbamoyl-oxirane-2-carboxylate;
    15-sodium (2P. ,, 3R) -3- (S) -3-methyl-1- (72-pyrimidinyl 7-piperazin-1-ylcarbonyl) -butylcarbamoyl-oxirane 2-carboxylate;
    16-sodium- (2E., 3R) -3- (S) -3-ketyl-1- (4-72-pyrimidinyl 7) piperazine-1-sh1carbonyl) butylcarbamoyl-α-oxirane-2-carboxylate.
    31 13
    The mortality of the animals in the control group, in which no medicinal substance was injected into the body, was approximately 14.1-14.9%, while the mortality of the animals in which the proposed medicinal compounds were injected was 9.8-11.9%.
    Thus, the proposed medicinal substances reduce mortality in myocardial infarction.
    For the determination of acute toxicity, male ddN mice weighing 20-28 g were used as experimental animals. Drug compounds were injected intravenously into the body of mice through the tail;
    The results are shown in Table. 2
    Table 2

    174
    MLD more than 1125
    MLD more than 1125
    MLD over i125
    MLD more than 1125
    MLD 1000-1125,
    MLD more than 1125
    MLD more than 1125
    440

    374
    345
    MLD more than 1125
    MLD more than 1125
    MLD more than 1125
    28
    32 Continuation of table 2
    Verapamilhydrochloride (dissolved in physiological sodium chloride solution)
    Note. MLD - minimal
    lethal dose.
    Even in those experiments, when medicinal compounds I were injected into the organism of animals in a dosage of up to 1 g / kg of live weight, in most cases no changes were noted. Thus, experiments confirmed that the proposed compounds are characterized by a low level of toxicity.
    Example 16 Drug (tablets).
    Film-coated tablets were prepared, each of the 220 mg tablets having the following composition, mg: Sodium trans-E- - (3) -3-methyl-1- - (4- / 2-pyrimidinyl) piperazine- -1-ylcarbonyl) -butylcarbamoylJ-oxyran-2-carboxylate50
    Lactose100
    Crystal
    pulp50
    Magnesium stearate 1.
    Hydroxypropylmethyl Cellulose15
    Hydroxypropylcellulose4
    Other compounds may be incorporated into film-coated tablets. of formula I.
    Example 17. The drug (granules).
    Prepared granules, each gram of which contains mg:
    Sodium trans-3- - (S) -1- (4-diphenylmethylpiperizin-1 -ylcarbonyl) -3-methylbutylcarbamoyl 33131816134
    α-oxirane-2-carbox-K of this composition is added
    silat200 sterilized distilled water
    Lactose 500 in an amount necessary for the delivery of corn starch 300 in total volume of liquid to 10 ml. The composition of the granules may include j
    these compounds. b. A preparation was prepared in Example 18, Medicinal Puffs, which contained 20 mg of ethyl
    drug (for injection) .- (2R, 3R) -3- (5) -3-methyl-1- (4- / 2,3,4t
    A. The preparation was prepared in trimethoxyphenylmethyl / -piperazin-1ampules, which was characterized by 10-ylcarbonyl) -butylcarbamoyl-oxyranedine with the composition: sodium-trans-3--2-carboxylate (hemisulfate). To this
    - (8) -3-methyl-1- (4- / 2,3,4-trimethoxy-composition is added sterilized
    phenylmethyl / -piperazin-1-ylcarbonyl) distilled water in an amount
    -butylcarbamoyl-oxiran-2-carboxy-necessary to bring the total amount too too mg; Primary 15em buffer solution to 100 ml.
    potassium acid phosphate (0.4 M per formulation for injection
    solution) 1 MP. You can enter other compounds I.
    权利要求:
    Claims (3)
    [1]
    1. The method of obtaining piperazine derivatives of General formula I
    H ^^ conh- (JH-co-n0nr 2
    RjOOC ”
    N
    CH (CH3 where R n is a hydrogen atom or a straight or branched chain alkyl group containing 1-4 carbon atoms;
    Rj is a straight chain alkyl group containing 1-4 carbon atoms;
    where η = 0-3, cinnamyl, diphenylmethyl, (2-pyridinyl), (2-pyrimidinyl), or their pharmaceutically acceptable salts, characterized in that the optically active or racemic compound of General formula II
    U ^ COOH
    RgOOC Η where is R - a straight or branched chain alkyl group containing 1-4 carbon atoms is reacted with a compound of the general formula III cr 2
    CH (SVD g wherein R t has the abovementioned meaning, in the presence of condensing agents - N-hydroxysuccinimide and Ν, Ν'-dicyclohexylcarbodiimide in an organic solvent selected from the group consisting of a methylene chloride - and 'ethyl acetate to give the compounds of general formula IV
    HyR ^ CONH-CH-CO-N ^ NRj, R, OOC H C Ng where and R 3 have the indicated meanings, followed by, if necessary, removal of the ester residue.
    [2]
    2. The method of pop. ^ characterized in that as the starting compound of the general formula II, an optically active compound SU, 1318161 AZ is used, some of the general formula II containing an epoxy group, or a potassium salt thereof.
    [3]
    3. A method of obtaining piperazine derivatives of General formula 1A
    H O CONH-CH-CO-nOm-R, where R 4 is an alkyl group containing 1-4 carbon atoms,
    R f - 2,3,4-trimethoxyphenylmethyl,. (2-pyrimidinyl), or their pharmaceutically acceptable salts, characterized in that the compound of General formula V
    Hx / Q zcmi-CH-cooH
    TCEP H where R 4 has the indicated meanings, is reacted with a compound of the general formula VI hnQn-Rj where R f has the indicated meanings. in the presence of condensing agents - N-oxysuccinimide or N-hydroxybenzotriazole and Ν, Ν'-dicyclohexylcarbodiimide in ethyl acetate.
    类似技术:
    公开号 | 公开日 | 专利标题
    US4330677A|1982-05-18|Polyether compounds, their production and their medicinal use
    RU2089550C1|1997-09-10|1,4-benzothiazepine derivative
    US5098892A|1992-03-24|Process for preparation of bicyclic compounds
    EP0262399A2|1988-04-06|Cyclic enol derivatives, production and use thereof
    FR2513250A1|1983-03-25|NEW SUBSTITUTED CYCLOBUTENE-3,4-DIONES
    EP0172458A2|1986-02-26|Novel biologically active compound having anti-prolyl endopeptidase activity
    DE2705025A1|1977-08-11|XANTHIN DERIVATIVES, THE METHOD OF MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THEM
    SU1318161A3|1987-06-15|Method for producing piperazine derivatives or pharmaceutically acceptable salts thereof |
    EP0224272B1|1991-02-06|Pyrrolidinylamide ester derivative having anti-prolyl endopeptidase activity, its synthesis and use and a pharmaceutical composition containing it
    WO1991016337A1|1991-10-31|S-|-substituted glutathione derivative
    KR100300566B1|2001-11-22|Pyrimidinone derivative and method for preparation thereof
    US4499286A|1985-02-12|Derivatives of thienylacetic acid amides and their pharmaceutically acceptable acid salts and a process for the preparation thereof
    US4134991A|1979-01-16|Derivatives of 2-|-acetic acid
    CA2127066A1|1994-12-31|.alpha.-amino acids derivatives, their preparation process and pharmaceutical compositions containing them
    US4241076A|1980-12-23|Halogenated substituted mercaptoacylamino acids
    US5747521A|1998-05-05|N-cinnamoyl-2-methyl-5-methoxy-3-indoleacetic acid ester, and pharmaceutical preparation containing the same
    US5451606A|1995-09-19|Anthraquinone compounds useful to treat osteoarticular conditions, pharmaceutical compositions and method of treatment
    KR850000845B1|1985-06-17|Process for preparing pyrrolidine derivatives
    US4285935A|1981-08-25|Dehydropeptide compounds, their production and their medical use
    EP0301936A1|1989-02-01|Piperidine derivatives, their preparation and their therapeutical use
    US4379792A|1983-04-12|Anti-inflammatory composition
    US6262060B1|2001-07-17|Azacycloalkane derivatives, preparation and therapeutic application
    SU791241A3|1980-12-23|Method of preparing 4,5,6,7-tetrahydroimidazo/4,5c/pyridine derivatives
    US4275068A|1981-06-23|Lipid lowering alkylene glycols and ester derivatives thereof
    CH681624A5|1993-04-30|
    同族专利:
    公开号 | 公开日
    ES8402288A1|1984-01-16|
    CH650504A5|1985-07-31|
    KR830010106A|1983-12-26|
    DE3212882A1|1982-10-28|
    MX7583E|1989-11-30|
    US4596803A|1986-06-24|
    GB2098204A|1982-11-17|
    JPH0154349B2|1989-11-17|
    NL8201509A|1982-11-01|
    FR2503709B1|1985-03-22|
    ES511174A0|1984-01-16|
    DD202567A5|1983-09-21|
    CA1166637A|1984-05-01|
    AU545938B2|1985-08-08|
    US4507297A|1985-03-26|
    KR880000786B1|1988-05-09|
    HU189574B|1986-07-28|
    ES525245A0|1985-07-16|
    IT8267485D0|1982-04-09|
    FR2503709A1|1982-10-15|
    JPS57169478A|1982-10-19|
    IT1156459B|1987-02-04|
    DE3212882C2|1991-02-07|
    AU8227182A|1982-10-14|
    ES8506304A1|1985-07-16|
    BR8202085A|1983-03-22|
    GB2098204B|1984-08-15|
    NL191690C|1996-03-04|
    NL191690B|1995-11-01|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US2963482A|1957-09-09|1960-12-06|Lilly Co Eli|Bis-epoxypropyldiamines|
    US2963483A|1958-12-22|1960-12-06|Union Carbide Corp|Nu-glycidylpiperazine and method of making it|
    US4032567A|1972-02-16|1977-06-28|Schering Aktiengesellschaft|Triiodoisophthalic acid monoamino acid amides, process for the preparation thereof, and use thereof as x-ray contrast media|
    GB1595168A|1977-03-03|1981-08-12|Taisho Pharma Co Ltd|Expoxysuccinic acid derivatives|
    JPS6155509B2|1978-09-30|1986-11-28|Taisho Pharma Co Ltd|
    JPH0154348B2|1979-02-27|1989-11-17|Taisho Pharma Co Ltd|
    JPS6320820B2|1979-05-17|1988-04-30|Taisho Pharma Co Ltd|
    JPS58126879A|1982-01-25|1983-07-28|Nippon Chemiphar Co Ltd|Optically active piperazine derivative and preventive and remedy for cardiac infarction|JPH0415787B2|1983-10-19|1992-03-19|Taisho Pharma Co Ltd|
    FR2680508B1|1991-08-20|1995-03-03|Adir|NOVEL 1-PIPERAZINE AMIDE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.|
    ES2062943B1|1993-03-23|1995-11-16|Uriach & Cia Sa J|NEW DERIVATIVES OFCYANOMETILPIPERAZINES.|
    US5556853A|1993-10-29|1996-09-17|Takeda Chemical Industries, Ltd.|Epoxysuccinic acid derivatives|
    CA2226740A1|1995-07-13|1997-01-30|Mitsuyoshi Azuma|Piperazine derivative and its uses|
    US5733911A|1996-01-26|1998-03-31|Hitachi Chemical Co., Ltd.|Method for inducing death of neoplastic cells using piperazne derivatives|
    WO1999011640A1|1997-09-04|1999-03-11|Nippon Chemiphar Co., Ltd.|Epoxysuccinamide derivatives|
    AU3459999A|1998-04-27|1999-11-16|Warner-Lambert Company|Substituted diarylalkyl amides as calcium channel antagonists|
    WO2007071035A1|2005-12-19|2007-06-28|Neuromed Pharmaceuticals Ltd.|Heterocyclic amide derivatives as calcium channel blockers|
    US8673904B2|2006-06-13|2014-03-18|The Board Of Trustees Of The Leland Stanford Junior University|Epoxide inhibitors of cysteine proteases|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    JP56053116A|JPH0154349B2|1981-04-10|1981-04-10|
    [返回顶部]